Cutaneous side effects of medical tumor therapy;Kutane Nebenwirkungen der medikamentösen Tumortherapie

Hautarzt

Volumn 62, Issue 6, 2011, Pages 444-451

  Degen, A ^a   Alter, M ^a   Schenck, F ^a   Kapp, A ^a   Gutzmer, R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cutaneous side effects; Hand foot syndrome; Rash; Targeted therapies; Tumor therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; HAND FOOT SYNDROME; HUMAN; PAPULOPUSTULAR EXANTHEM; PARONYCHIA; RASH; SKIN CANCER; SKIN DISEASE;

EID: 85027946197     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-010-2042-4     Document Type: Article

References (30)

1. Meta-Analysis Group In Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537-3541
2. Arnault JP, Wechsler J, Escudier B et al (2009) Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 27:e59-e61
3. Balagula Y, Barth HK, Busam KJ et al (2010) Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs [Epub ahead of print]
4. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28
5. Lopez V, Pinazo I, Marti N et al (2008) Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect. J Eur Acad Dermatol Venereol 23:959-960
6. Chen M, Crowson AN, Woofter M et al (2004) Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 31:818-820 (Pubitemid 38451277)
7. Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 8:652-661
8. Degen A, Satzger I, Voelker B et al (2010) Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers. Dermatology 221:193-196
9. Eames T, Grabein B, Kroth J, Wollenberg A (2010) Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 24:958-960
10. Fox LP (2007) Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 56:460-465 (Pubitemid 46273839)
11. Gutzmer R, Becker JC, Enk A et al (2010) Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges 9:195-203
12. Gutzmer R, Werfel T, Kapp A, Elsner J (2006) Cutaneous side effects of EGF-receptor inhibition and their management. Hautarzt 57:509-513 (Pubitemid 43891893)
13. Gutzmer R, Werfel T, Mao R et al (2005) Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 153:849-851 (Pubitemid 41415923)
14. Hu JC, Sadeghi P, Pinter-Brown LC et al (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56:317-326 (Pubitemid 46091817)
15. Joncas V, Sammour R, Krasny M et al (2008) A distinct cutaneous reaction to sorafenib and a multikinase inhibitor. Int J Dermatol 47:767-769 (Pubitemid 352016099)
16. Lacouture ME, Reilly LM, Gerami P, Guitart J (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19:1955-1961
17. Lee WJ, Lee JL, Chang SE et al (2009) Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161:1045-1051
18. Marquez CB, Smithberger EE, Bair SM et al (2009) Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control 16:66-69
19. Potthoff K, Hofheinz R, Hassel JC et al (2010) Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 22:524-535
20. Reck M, Gutzmer R (2010) Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Onkologie 33:470-479
21. Robert C, Arnault JP, Mateus C (2010) RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 23:177-182
22. Robert C, Mateus C, Spatz A et al (2009) Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 60:299-305
23. Robert C, Soria JC, Spatz A et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491-500 (Pubitemid 40903630)
24. Smith KJ, Haley H, Hamza S, Skelton HG (2009) Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 35:1766-1770
25. Strumberg D, Awada A, Hirte H et al (2006) Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 42:548-556 (Pubitemid 43227936)
26. Ulrich J, Hartmann JT, Dorr W, Ugurel S (2008) Skin toxicity of anti-cancer therapy. J Dtsch Dermatol Ges 6:959-977
27. Valks R, Fraga J, Porras-Luque J et al (1997) Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol 133:873-878 (Pubitemid 27337548)
28. Wolf SL, Qin R, Menon SP et al (2010) Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28:5182-5187
29. Wollenberg A, Moosmann N, Kroth J et al (2007) Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid. Hautarzt 58:615-618 (Pubitemid 47087487)
30. Wollenberg A, Staehler M, Eames T (2010) Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib. Hautarzt 61:662-667